Biomarker testing in advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer: expert recommendations

Tomás Reinert, Ahmed S. Alshehri, Amr Shafik, Ching-Hung Lin, Gonzalo Gomez Abuin, Gyungyub Gong, Kyung Hae Jung, Mora Amat, Nirmala Pathmanathan, Samuel G. W, Samuel Rivera-Rivera, Shyam Aggarwal, Stephen J. Luen, Timothy Kwang Yong Tay

Therapeutic Advances in Medical Oncology

Published online on August 17, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Biomarker testing is central to precision oncology, enabling effective use of targeted therapies in hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). Recommendations for current and ...